“It is rare,” says title designer and Art of the Title editor-in-chief Lola Landekic. “It’s a very interesting choice. As a ...

Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful IPO in June 2024. The stock had been on a strong ...

Shares of Tempus AI (NASDAQ:TEM) dropped 19% Tuesday, the day after the AI-focused healthcare company released a Q4 earnings report that missed Street estimates and its 2025 financial forecast.

Tempus AI reports mixed fourth-quarter financial results. JPMorgan analyst Rachel Vatnsdal downgrades Tempus AI from Overweight to Neutral following the company's quarterly results. Our government ...

JPMorgan downgraded Tempus AI (TEM) to Neutral from Overweight with a price target of $55, up from $50. The company reported Q4 results in-line with the preannouncement and its 2025 guidance ...

Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in Q4 2024, with gross profit growth accelerating to 49.7%. The company ...

Please go ahead. Thank you, Jason. Good afternoon and welcome to Tempus' Fourth Quarter 2024 Conference Call. This afternoon Tempus released results for the quarter and year ended December 31 ...

16:52 EST Tempus AI (TEM) down 7% at $64.83 after Q4 earnings miss and guidance See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline your ...

Tempus AI stock faces mixed signals ahead of Q4 earnings, with short-term bearish pressure but technical support. Analysts see a 13.5% downside for Tempus AI, while technical indicators suggest ...

Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM stock by buying 50 of ...